Of exocytosis. This inhibitor of exocytosis was designed to target NSF, a critical component of the exocytic machinery (16?8). We developed a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits NSF. This fusion peptide, designated TAT-NSF222, inhibits NSF ATPase activity, decreases endothelial exocytosis, and blocks inflam
What is Plikli?

Plikli is an open source content management system that lets you easily create your own user-powered website.

Latest Comments